Salisbury Foundation Trust

FOI_5452

Internal Reference Number: FOI_5452

Date Request Received: 27/12/2019 11:54:33

Date Request Replied To: 27/01/2020 09:03:02

This response was sent via: By Email

Request Summary: Biologics and biosimilar prescribing in Rheumatology.

Request Category: Private Individuals

 
Question Number 1:
Could you please provide me with the following numbers of patients treated in the last 12 months with the following drugs

If you are unable to provide figures for the drugs listed above for prescribing within Rheumatology, then could you instead provide figures for the above but regardless of disease and indication

• Abatacept [Orencia]
• Adalimumab [Amgevita]
• Adalimumab [Hulio]
• Adalimumab [Humira]
• Adalimumab [Hyrimoz]
• Adalimumab [Imraldi]
• Apremilast [Otezla]
• Baricitinib [Olumiant]
• Brodalumab [Kyntheum]
• Certolizumab [Cimzia]
• Dimethyl fumarate [Skilarence]
• Etanercept [Benepali]
• Etanercept [Enbrel]
• Etanercept [Erelzi]
• Golimumab [Simponi]
• Guselkumab [Tremfya]
• Infliximab [Flixabi]
• Infliximab [Inflectra]
• Infliximab [Remicade]
• Infliximab [Remsima]
• Ixekizumab [Taltz]
• Risankizumab [Skyrizi]
• Rituximab [MabThera]
• Rituximab [Rixathon]
• Rituximab [Truxima]
• Sarilumab [Kevzara]
• Secukinumab [Cosentyx]
• Tildrakizumab [Ilumetri]
• Tocilizumab [Ro Actemra]
• Tofacitinib [Xeljanz]
• Upadacitinib [Rinvoq]
• Ustekinumab [Stelara
 
Answer To Question 1:
. Abatacept [Orencia] 52
. Adalimumab [Amgevita] 57
. Adalimumab [Hulio]
. Adalimumab [Humira] 152
. Adalimumab [Hyrimoz]
. Adalimumab [Imraldi] 190
. Apremilast [Otezla] 8
. Baricitinib [Olumiant] 92
. Brodalumab [Kyntheum] 1
. Certolizumab [Cimzia] 50
. Dimethyl fumarate [Skilarence]
. Etanercept [Benepali] 182
. Etanercept [Enbrel] 20
. Etanercept [Erelzi]
. Golimumab [Simponi] 41
. Guselkumab [Tremfya] 1
. Infliximab [Flixabi]
. Infliximab [Inflectra] 27
. Infliximab [Remicade] 10
. Infliximab [Remsima]
. Ixekizumab [Taltz] 14
. Risankizumab [Skyrizi]
. Rituximab [MabThera] 16
. Rituximab [Rixathon]
. Rituximab [Truxima] 95
. Sarilumab [Kevzara] 2
. Secukinumab [Cosentyx] 30
. Tildrakizumab [Ilumetri]
. Tocilizumab [Ro Actemra] 65
. Tofacitinib [Xeljanz] 51
. Upadacitinib [Rinvoq]
. Ustekinumab [Stelara 16
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2021 Salisbury NHS Foundation Trust
Trust Values